HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells
Takaaki Oba, Mayu Ono, Hisanori Matoba, Takeshi Uehara, Yoshie Hasegawa, Ken‐ichi Ito
Topics & Concepts
EribulinCancer researchAcetylationSKBR3Triple-negative breast cancerVorinostatBreast cancerHDAC6CancerMedicineChemistryInternal medicineMetastatic breast cancerHistone deacetylaseHistoneBiochemistryHuman breastGeneHistone Deacetylase Inhibitors ResearchCancer Treatment and PharmacologyPlant-derived Lignans Synthesis and Bioactivity